Only a small number of men who were prescribed testosterone therapy received\u00a0appropriate, guideline-concordant\u00a0diagnostic testing, according to a study being presented Saturday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, Ill, by Sophia Sinha, M.D., clinical assistant professor at the University of Michigan in Ann Arbor, Mich.<\/p>\n
<\/p>\n
Our study findings highlight opportunities to improve patient care and reduce inappropriate\u00a0testosterone prescribing. Long-term, these findings can lead to quality-improvement efforts and clinical decision support\u00a0tools\u00a0that promote consistent, guideline-concordant testosterone prescribing.”<\/p>\n
\n
<\/p>\n
Maria Papaleontiou, M.D.,\u00a0senior author,\u00a0associate professor at the University of Michigan\u00a0in Ann Arbor, Mich.<\/p>\n
<\/p>\n
The retrospective chart review included a random sample of 200 males assigned at birth (mean age, 52.5 years) with at least one outpatient primary care visit at Michigan Medicine in the past year, who had a diagnosis of hypogonadism, and received an initial testosterone prescription during the study period (2020 to 2025).<\/p>\n
The most common\u00a0coexisting medical\u00a0conditions\u00a0in the study population\u00a0included obesity (63%), hypertension (52%), depression (40%), diabetes (28%)\u00a0and\u00a0arthritis (28%).<\/p>\n
That data show only 12% of men who received\u00a0an initial\u00a0testosterone\u00a0prescription\u00a0had two low morning testosterone levels (total testosterone < 300ng\/dL), free testosterone < 70pg\/mL, or low bioavailable testosterone, between 5 a.m. and 10 a.m.), had their LH and\/or FSH measured, and\u00a0had\u00a0no contraindications to testosterone therapy.<\/p>\n